E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Treatment of fibromyalgia |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 6.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10048439 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10048439 |
E.1.2 | Term | Fibromyalgia |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is To evaluate the efficacy and safety of pregabalin BID compared with placebo for the symptomatic relief of pain in patients with fibromyalgia. If the first objective is met, then the second primary objective will be To evaluate the efficacy and safety of pregabalin BID compared with placebo for the symptomatic relief of pain and improvement of global impressions in patients with fibromyalgia. |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the efficacy of pregabalin BID compared with placebo for improvement in sleep, function, fatigue, health-related quality of life, and mood disturbance associated with fibromyalgia. |
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
1. Male or female of any race, at least 18 years of age; 2. Female patients must be nonpregnant and nonlactating; additionally they must be postmenopausal, surgically sterilized, or using an appropriate method of contraception. All women must have a confirmed negative serum pregnancy test at screening V1 prior to the randomization visit; 3. Patients must be willing and able to understand and cooperate with study procedures; 4. Patients must have personally signed and dated a legally effective written informed consent prior to admission to the study; 5. At screening V1 , patients must meet the ACR criteria for fibromyalgia ie, widespread pain present for at least 3 months, and pain in at least 11 of 18 specific tender point sites ; 6. At screening V1 and randomization V2 , patients must have a score of 7 40 mm on the Pain Visual Analog Scale VAS ; 7. At randomization V2 , at least 4 pain diaries must be completed satisfactorily within the last 7 days and the average pain score must be / 4. |
|
E.4 | Principal exclusion criteria |
1. Patients with / 30 decrease on the Pain Visual Analog Scale VAS at randomization V2 as compared to screening V1 ; 2. Patients with other severe pain due to other conditions eg, DPN or PHN that may confound assessment or self-evaluation of the pain associated with fibromyalgia; 3. Patients with any widespread inflammatory musculoskeletal disorders, widespread rheumatic diseases other than fibromyalgia, active infections, or untreated endocrine disorders; 4. Previous participation in a clinical trial with pregabalin, previous exposure to pregabalin or currently on pregabalin for any condition; 5. Patients with severe depression that in the judgment of the investigator, would make the patient inappropriate for entry into this trial; 6. Patients with serious hepatic, respiratory, neurologic epilepsy, multiple sclerosis , hematologic or immunologic illnesses, an unstable cardiovascular disease, or any other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of trial results in the judgment of the investigator; 7. Patients with active malignancy of any type or a history of a malignancy with the exception of patients with malignancy surgically removed with no evidence of recurrence within 5 years before enrollment and patients with a history of treated basal cell carcinoma ; 8. Patients who are immunocompromised; 9. Patients with a history of illicit drug or alcohol abuse within the last 2 years; 10. CLcr / 60 mL/min estimated from serum creatinine . Patients whose CLcr estimated from serum creatinine is / 60 mL/min may submit a 24-hour urine sample for analysis by central laboratory. If the CLcr value based on 24-hour CLcr test is 60 mL/min, patient is eligible for the study. 11. Platelet count 100 x 109/L; white blood cell WBC count 2.5 x 109/L; neutrophil count 1.5 x 109/L; 12. Erythrocyte sedimentation rate ESR 40 mm/h; 13. Abnormal antinuclear antibody ANA / 3 U , or rheumatoid factor RF 80 IU/mL ; 14. Abnormal clinically relevant 12-lead electrocardiogram ECG ; 15. Patients taking any other experimental drugs within 30 days prior to screening V1 ; 16. Patients with active GI disease including any GI surgery that in the opinion of the investigator would interfere with the absorption of study medication; 17. Patients with difficulties swallowing capsules or unable to tolerate oral medication; 18. Use of prohibited pain/sleep medications including antidepressants, sedatives, hypnotics, NSAIDs, opiates, muscle relaxants in the absence of appropriate washout periods 19. Patients with pending disability claims or currently receiving monetary compensation pertinent to the patient s fibromyalgia or co-morbid diseases. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Endpoint mean pain score, defined as the mean of the last 7 pain diary entries in the study while the patient is on study medication. If the first objective is positive efficacy in endpoint mean pain , 1 additional endpoint will be assessed for the second objective Patient Global Assessment Patient Global Impression of Change at Termination Visit. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | Information not present in EudraCT |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 12 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 12 |